Hikma Lines Up US Hybrid Injectable
Deal With Arecor For Undisclosed Drug
Hikma has struck a deal to develop with the UK’s Arecor a ready-to-use injectable that will be filed under the US 505(b)(2) hybrid regulatory pathway.
Hikma has struck a deal to develop with the UK’s Arecor a ready-to-use injectable that will be filed under the US 505(b)(2) hybrid regulatory pathway.